Juluca® (dolutegravir/rilpivirine) – New drug approval
November 21, 2017 – The FDA announced the approval of ViiV Healthcare’s Juluca (dolutegravir/rilpivirine) as a complete regimen for the maintenance treatment of human immunodeficiency virus (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral (ART) regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.
Top